Biogen and Stoke Therapeutics Present Data that Further Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet ...

Long-term Phase 1/2a and open label extension (OLE) data for zorevunersen on top of standard of care anti-seizure medicines (ASMs)demonstrate ...

Rapport Therapeutics Announces New Data and Post Hoc Analysis Demonstrating the Magnitude and Consistency of RAP-219’s Clinical Response in Patients with Focal Onset Seizures

Post-hoc analysis of RAP-219 Phase 2a data showed early onset of action and consistency of median response over the entire treatment period, ...
TMCnet

Biogen and Stoke Therapeutics Present Data that Further Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet ...

—Long-term Phase 1/2a and open label extension (OLE) data for zorevunersen on top of standard of care anti-seizure medicines (ASMs) demonstrate durable seizure reductions, including increases in ...
MedPage Today on MSN

Early results amaze for one-time Dravet syndrome treatment

ETX101 uses an adeno-associated viral (AAV) vector to deliver a transcription factor for the SCN1A gene, given by ...
IEEE

The Method of Spatiotemporal-Frequency Multidimensional Feature Fusion Based on Emotional EEG Signals

Abstract: Emotion recognition technology is an important research direction in the field of artificial intelligence and emotional computing, and it has been widely used in the fields of mental health, ...